What is TuHURA Biosciences, Inc.'s D&A?

TuHURA Biosciences, Inc. (HURA) reported D&A of $23.47K in Q1 2026.

How has TuHURA Biosciences, Inc.'s D&A changed year-over-year?

TuHURA Biosciences, Inc.'s D&A increased by 67.0% year-over-year, from $14.06K to $23.47K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

TuHURA Biosciences, Inc. HURA D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

Inhibrx Biosciences, Inc.INBX

$537K-20.4%

Corvus PharmaceuticalsCRVS

$29K+31.8%

ImmunityBio, Inc.IBRX

$4.38M+14.4%

Avalo TherapeuticsAVTX

$17K-87.4%

Janux TherapeuticsJANX

$469K-9.6%

Other financials

Income statement

See full

Revenue-—

Net income-$7.5M-13.1%

EPS (diluted)-$0.13+13.3%

Balance sheet

See full

Cash & equivalents$6.3M+1.3%

Total debt$456.9K+178%

Total equity$23.2M+135%

Total assets$29.7M+103%

Cash flow

See full

Operating cash flow-$4.4M+6.9%

CapEx$48.8K+14.5%

Free cash flow-$4.5M+6.7%

Valuation

See full

Market cap$155.39M+45.8%

Enterprise value$149.54M+52.3%

Returns & leverage

See full

Return on equity-187.2%—

Debt / equity0×0.0×

Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s D&A?: TuHURA Biosciences, Inc. (HURA) reported D&A of $23.47K in Q1 2026.
How has TuHURA Biosciences, Inc.'s D&A changed year-over-year?: TuHURA Biosciences, Inc.'s D&A increased by 67.0% year-over-year, from $14.06K to $23.47K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.